Effects of Oral Sildenafil on Mortality in Adults With PAH

A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 385 participants.

Also called NCT02060487

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 385 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02060487
  • EudraCT 2013-004362-34
Other papers using this trial's data
  • Randomized, Multicenter Study to Assess the Effects of Different Doses of Sildenafil on Mortality in Adults With Pulmonary Arterial Hypertension Circulation, 2024-06-18 DOI, PubMed 38752352

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Belgium, Bosnia & Herzegovina, Croatia, Czechia, Germany, Greece, Hong Kong SAR China, Israel, Latvia, Malaysia, Mexico, Poland, Romania, Russia, Serbia, Singapore, South Africa, Spain, Thailand, Türkiye, Ukraine (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT02060487. Randomized; quadruple masking; primary purpose treatment. Start 2014-09-22 (actual); primary completion 2021-02-26 (actual). Results posted on 2022-05-10.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effects of Oral Sildenafil on Mortality in Adults With PAH
Acronym
AFFILIATE
Condition
Pulmonary Arterial Hypertension
Intervention (Drug)
sildenafil citrate
Intervention (Drug)
sildenafil citrate
Intervention (Drug)
sildenafil citrate
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (class: industry)

Record details

Record id
cardio:ct-nct02060487
Content hash
d55aeab5d41092732f6035d7ecfb7f591fdb843e38a082f66c73b493406efe52